Roland Goldbrunner, Nicolas Foroglou, Francesco Signorelli, Philippe Schucht, Asgeir S Jakola, Giuseppe Minniti, Radoslaw Rola, Mirjam Renovanz, Matthias Preusser, Julia Furtner, Rachel Grossman, Christian Mawrin, Andreas Demetriades, Michael Weller, Matthias Simon
{"title":"EANS-EANO Guidelines on the extent of resection in gliomas.","authors":"Roland Goldbrunner, Nicolas Foroglou, Francesco Signorelli, Philippe Schucht, Asgeir S Jakola, Giuseppe Minniti, Radoslaw Rola, Mirjam Renovanz, Matthias Preusser, Julia Furtner, Rachel Grossman, Christian Mawrin, Andreas Demetriades, Michael Weller, Matthias Simon","doi":"10.1093/neuonc/noaf217","DOIUrl":null,"url":null,"abstract":"<p><p>Intense efforts are employed to optimize neurosurgical resection of gliomas in different clinical scenarios. However, the level of evidence employed towards personalised treatment decisions is still moderate. Therefore, a joint task force was created by the European Association for Neurosurgical Societies (EANS) and the European Association of Neuro-Oncology (EANO) in order to provide interdisciplinary guidance on the extent of resection (EOR) in glioma surgery. This task force assessed the data on the EOR in gliomas, evaluated the level of evidence and composed recommendations. The EOR is determined routinely by postoperative magnetic resonance imaging (MRI). Since EOR may be associated with survival and may have an impact on epilepsy, neurocognition, quality of life, neurological status and also on planning of radiation and pharmacotherapy (evidence classes I-IV), recommendations of different levels can be made for the resection of newly diagnosed glioblastomas (level A), recurrent glioblastomas (level C), newly diagnosed (level B) and recurrent (good practice point) IDH mutant gliomas, ependymomas in children (level B) and adults (good practice point) as well as World Health Organization (WHO) CNS grade 1 tumors (good practice point). We hereby report the outcome of this collaborative effort by the joint task force between EANS and EANO.</p>","PeriodicalId":19377,"journal":{"name":"Neuro-oncology","volume":" ","pages":""},"PeriodicalIF":13.4000,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro-oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/neuonc/noaf217","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Intense efforts are employed to optimize neurosurgical resection of gliomas in different clinical scenarios. However, the level of evidence employed towards personalised treatment decisions is still moderate. Therefore, a joint task force was created by the European Association for Neurosurgical Societies (EANS) and the European Association of Neuro-Oncology (EANO) in order to provide interdisciplinary guidance on the extent of resection (EOR) in glioma surgery. This task force assessed the data on the EOR in gliomas, evaluated the level of evidence and composed recommendations. The EOR is determined routinely by postoperative magnetic resonance imaging (MRI). Since EOR may be associated with survival and may have an impact on epilepsy, neurocognition, quality of life, neurological status and also on planning of radiation and pharmacotherapy (evidence classes I-IV), recommendations of different levels can be made for the resection of newly diagnosed glioblastomas (level A), recurrent glioblastomas (level C), newly diagnosed (level B) and recurrent (good practice point) IDH mutant gliomas, ependymomas in children (level B) and adults (good practice point) as well as World Health Organization (WHO) CNS grade 1 tumors (good practice point). We hereby report the outcome of this collaborative effort by the joint task force between EANS and EANO.
期刊介绍:
Neuro-Oncology, the official journal of the Society for Neuro-Oncology, has been published monthly since January 2010. Affiliated with the Japan Society for Neuro-Oncology and the European Association of Neuro-Oncology, it is a global leader in the field.
The journal is committed to swiftly disseminating high-quality information across all areas of neuro-oncology. It features peer-reviewed articles, reviews, symposia on various topics, abstracts from annual meetings, and updates from neuro-oncology societies worldwide.